BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9217046)

  • 1. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.
    Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
    Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
    Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
    Albertini MR; Gan J; Jaeger P; Hank JA; Storer B; Schell K; Rivest T; Surfus J; Reisfeld RA; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):278-95. PubMed ID: 8877722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
    Gilman AL; Ozkaynak MF; Matthay KK; Krailo M; Yu AL; Gan J; Sternberg A; Hank JA; Seeger R; Reaman GH; Sondel PM
    J Clin Oncol; 2009 Jan; 27(1):85-91. PubMed ID: 19047298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.
    Yu AL; Uttenreuther-Fischer MM; Huang CS; Tsui CC; Gillies SD; Reisfeld RA; Kung FH
    J Clin Oncol; 1998 Jun; 16(6):2169-80. PubMed ID: 9626218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
    Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
    Cheung NK; Lazarus H; Miraldi FD; Abramowsky CR; Kallick S; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF; Berger NA
    J Clin Oncol; 1987 Sep; 5(9):1430-40. PubMed ID: 3625258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
    Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
    J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.
    Handgretinger R; Baader P; Dopfer R; Klingebiel T; Reuland P; Treuner J; Reisfeld RA; Niethammer D
    Cancer Immunol Immunother; 1992; 35(3):199-204. PubMed ID: 1638557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
    Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
    Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
    Murray JL; Cunningham JE; Brewer H; Mujoo K; Zukiwski AA; Podoloff DA; Kasi LP; Bhadkamkar V; Fritsche HA; Benjamin RS
    J Clin Oncol; 1994 Jan; 12(1):184-93. PubMed ID: 8270976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.